University of Alberta
🇨🇦Canada
- Country
- 🇨🇦Canada
- Ownership
- Private
- Established
- 1908-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.ualberta.ca
A Cluster-randomized Controlled Knowledge Translation Feasibility Study in Alberta Community Pharmacies
Not Applicable
Completed
- Conditions
- Chronic Diseases
- Interventions
- Behavioral: Task-focused facilitation
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2023-01-05
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 10
- Registration Number
- NCT02191111
- Locations
- 🇨🇦
EPICORE Centre, University of Alberta, Edmonton, Alberta, Canada
Comprehensive Program for Youth Mental Health
Not Applicable
Completed
- Conditions
- SuicideAnxietyDepression
- Interventions
- Behavioral: Smart, Positive, Active, Realistic X-factor thoughts (SPARX)Behavioral: Breaking FreeBehavioral: This Way UpBehavioral: Resiliency Training
- First Posted Date
- 2014-06-23
- Last Posted Date
- 2015-12-10
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 5514
- Registration Number
- NCT02169960
- Locations
- 🇨🇦
Red Deer Public Schools, Red Deer, Alberta, Canada
Asia Africa Streptokinase Trial
- First Posted Date
- 2014-05-30
- Last Posted Date
- 2022-05-27
- Lead Sponsor
- University of Alberta
- Registration Number
- NCT02150785
The Middle East Dual Anti-platelet Treatment in Acute Transient Ischemic Attack
Phase 4
Withdrawn
- Conditions
- Minor StrokeTransient Ischemic Attacks
- Interventions
- Drug: anti-thrombotic treatment using Aspirin (ASA 75-325mg) and Clopidogrel (75mg)
- First Posted Date
- 2014-05-22
- Last Posted Date
- 2022-05-27
- Lead Sponsor
- University of Alberta
- Registration Number
- NCT02144831
- Locations
- 🇨🇦
University of Alberta Hospital, Edmonton, Alberta, Canada
Acetyl-l-carnitine to Enhance Nerve Regeneration in Carpal Tunnel Syndrome
Phase 2
Completed
- Conditions
- Compression NeuropathyCarpal Tunnel Syndrome
- Interventions
- Drug: Acetyl-l-carnitineDrug: placebo
- First Posted Date
- 2014-05-16
- Last Posted Date
- 2017-10-27
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 20
- Registration Number
- NCT02141035
- Locations
- 🇨🇦
University of Alberta Hospital, Edmonton, Alberta, Canada
🇨🇦Glenrose Hosptial, Edmonton, Alberta, Canada
🇨🇦Royal Alexandra Hospital, Edmonton, Alberta, Canada
Milk-derived Gangliosides for Inflammatory Bowel Disease
Phase 1
Withdrawn
- Conditions
- Inflammatory Bowel Disease
- Interventions
- Dietary Supplement: PlaceboDietary Supplement: Ganglioside
- First Posted Date
- 2014-05-15
- Last Posted Date
- 2022-07-18
- Lead Sponsor
- University of Alberta
- Registration Number
- NCT02139709
- Locations
- 🇨🇦
Zeidler Ledcor gastroenterology clinic, Edmonton, Alberta, Canada
Timing of Indomethacin Administration for the Prevention of Post-ERCP Pancreatitis (PEP)
Phase 4
Completed
- Conditions
- Acute Pancreatitis
- Interventions
- Drug: Rectal indomethacin 100mg one time before or after ERCP
- First Posted Date
- 2014-04-11
- Last Posted Date
- 2017-10-25
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 534
- Registration Number
- NCT02111707
- Locations
- 🇨🇦
University of Alberta, Edmonton, Alberta, Canada
Penumbral Based Novel Thrombolytic Therapy in Acute Ischemic Stroke
Phase 2
Completed
- Conditions
- Cerebral InfarctionBrain IschemiaStroke
- Interventions
- First Posted Date
- 2014-04-02
- Last Posted Date
- 2018-04-06
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 20
- Registration Number
- NCT02101606
- Locations
- 🇨🇦
University of Alberta, Edmonton, Alberta, Canada
Solar Powered Oxygen Delivery
Phase 2
Completed
- Conditions
- HypoxemiaPneumonia
- Interventions
- Device: Solar powered oxygenDevice: Oxygen from cylinders
- First Posted Date
- 2014-04-01
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 130
- Registration Number
- NCT02100865
- Locations
- 🇺🇬
Jinja Regional Referral Hospital, Jinja, Uganda
Outcomes of Angiotensin Converting Enzyme Inhibitor Management Strategies Prior to Coronary Artery Bypass
Phase 2
Completed
- Conditions
- Coronary Artery Disease
- Interventions
- Drug: ACE/ARB withdrawalDrug: ACE/ARB continuation
- First Posted Date
- 2014-03-26
- Last Posted Date
- 2018-03-22
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 126
- Registration Number
- NCT02096406
- Locations
- 🇨🇦
University of Alberta Hospital, Edmonton, Alberta, Canada
© Copyright 2025. All Rights Reserved by MedPath